OKEX or OKX, as they have recently rebranded to (more on that later), is a large cryptocurrency exchange and one of the OG’s in the crypto space established all the way back in 2016. Using its expertise in the spot market, OKX offers its users the opportunity to trade Futures, perpetual swaps and options markets. In […]

The post OKX Exchange: Complete Rebranding Overview appeared first on Coin Bureau.

Rune Token rallies by double digits after the announcement of the new features, in the past 24 hours as we can see more today in our latest cryptocurrency news today. The DeFi project ThorChain launched new updates and the rUNE token rallied right after the announcement. Thorchain is up by 18% over the past 24 […]

The crypto market has been up and down lately. The volatile market is just…

The post The best altcoins to kickstart your March Investment Journey appeared first on Coin Journal.

TOKYO, Mar 11, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced today the company will present research from its robust Alzheimer's disease (AD) pipeline, including the latest findings on lecanemab, Eisai's investigational anti-amyloid beta (Abeta) protofibril antibody for the treatment of early AD at the AD/PD 2022 International Conference on Alzheimer's and Parkinson's Diseases (AD/PD) from March 15-20 in Barcelona, Spain and virtually.

The lecanemab data and additional research findings from Eisai's clinical development programs will be featured in 13 presentations. Lecanemab was granted Breakthrough Therapy and Fast Track designations by the U.S. Food and Drug Administration (FDA) in June and December 2021, respectively. Eisai anticipates completing lecanemab's rolling submission of a Biologics License Application for the treatment of early AD to the FDA under the accelerated approval pathway in the first quarter of Eisai's fiscal year 2022, which begins April 1, 2022. Additionally, the readout of the Phase 3 confirmatory Clarity AD clinical trial will occur in the Fall of 2022. Eisai initiated a submission to the Pharmaceuticals and Medical Devices Agency (PMDA) of application data of lecanemab under the prior assessment consultation system in Japan in March 2022.

"Four key presentations at AD/PD 2022 advance our understanding of the mechanism of action of Eisai's investigational anti- Abeta protofibril antibody lecanemab and the therapy's clinical and safety profile, including amyloid related imaging abnormalities, or ARIA, from the Phase 2b study and open-label extension, in the potential treatment of early Alzheimer's disease," said Michael Irizarry, M.D., Senior Vice President, Deputy Chief Clinical Officer, Neurology Business Group, Eisai Inc. "In addition to lecanemab, Eisai's robust pipeline includes compounds targeting the tau pathway, other pathways leading to neurodegeneration, and the testing of combination therapies that may be the optimal approach to treat or even prevent Alzheimer's disease."

The focus on AD has historically been on alleviating cognitive, functional, and behavioral symptoms, but there has been significant progress in understanding the biological mechanisms of the disease. Eisai's investigational pipeline aims to treat the range of underlying pathophysiology, including amyloid, tau and neurodegeneration.

"Because of the robust design of the lecanemab Phase 2b study, Eisai was able to design the Phase 3 confirmatory Clarity AD clinical trial to optimally verify lecanemab's clinical efficacy and safety in early Alzheimer's disease," said Ivan Cheung, Chairman, Eisai Inc., Senior Vice President, President Neurology Business Group and Global Alzheimer's Disease Officer, Eisai Co., Ltd. "Part of the recruitment strategy for the Clarity AD confirmatory trial was to ensure greater inclusion of ethnic and racial populations. While there is still important work to be done in ensuring minority populations' participation in clinical trials, Eisai is proud that approximately 25% of the total U.S. enrollment in Clarity AD consists of African American and Hispanic persons living with early Alzheimer's disease, which mirrors the U.S. Medicare population."

This release discusses investigational uses of an agent in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that such investigational agent will successfully complete clinical development or gain health authority approval.

For more information, visit https://www.eisai.com/news/2022/news202218.html.


Copyright 2022 JCN Newswire. All rights reserved. www.jcnnewswire.comEisai Co., Ltd. announced today the company will present research from its robust Alzheimer's disease (AD) pipeline, including the latest findings on lecanemab, Eisai's investigational anti-amyloid beta (Abeta) protofibril antibody for the treatment of early AD at the AD/PD 2022 International Conference on Alzheimer's and Parkinson's Diseases (AD/PD) from March 15-20 in Barcelona, Spain and virtually.

Goldman is just one of multiple Wall Street banks allegedly exploring a similar product. 

Foundation also announced Envoy, a companion mobile Bitcoin wallet for the Passport Batch 2.

In this post, we present a solution for digitizing transactional documents using Amazon Textract and incorporate a human review using Amazon Augmented AI (A2I). You can find the solution source at our GitHub repository. Organizations must frequently process scanned transactional documents with structured text so they can perform operations such as fraud detection or financial […]

Data lakes have become the norm in the industry for storing critical business data. The primary rationale for a data lake is to land all types of data, from raw data to preprocessed and postprocessed data, and may include both structured and unstructured data formats. Having a centralized data store for all types of data […]

Cake DeFi is a Singapore-based fintech platform that makes DeFi (decentralized financial) services and apps available to everyone. The company has announced the creation of [...]

The post XRP To Top-5 Inevitable! Are These Indicators A Sign Of An Incoming 20% Rally? appeared first on Coinpedia - Fintech & Cryptocurreny News Media| Crypto Guide

  The world of cryptocurrencies continues to witness discussions revolving around the executive order from the White House, and its implications. Successively, the XRP army pins optimistic hopes around the implications of the executive order. As a number of governments’ interests remain the protocol’s imperative strengths. Whilst the community rejoices its growing strengths, investors and merchants …

In a bid to validate offshore fish environmental DNA (eDNA) survey methods, a new project has been launched – said to be the first of its kind to trial the use of eDNA to improve survey methods for offshore wind farm environmental impact assessments. Michelle Elliott, the Senior Environmental Consultant leading the project on behalf […]

Some designs focus on power, while others focus on sustainable performance, cost, or flexibility. But choosing the best option for an application based on benchmarks is becoming more difficult.

The post Why Comparing Processors Is So Difficult appeared first on Semiconductor Engineering.